Treatment of Truncated ALK-positive Bone Cancer Using Crizotinib (Xalkori) or Alectinib (Alecensa)

by | May 1, 2026 | Clinical Trials | 0 comments

​ Conditions: Bone Cancer; ALK-positive Bone Cancer; Truncated ALK (ALKATI)-Positive Malignancy

Interventions: Drug: Alectinib

Sponsors: China Medical University Hospital

Not yet recruiting Conditions: Bone Cancer; ALK-positive Bone Cancer; Truncated ALK (ALKATI)-Positive Malignancy
Interventions: Drug: Alectinib
Sponsors: China Medical University Hospital
Not yet recruiting 

Submit a Comment

Your email address will not be published. Required fields are marked *